Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


1,2-oxazoles (including hydrogenated)

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

514183000 - Heterocyclic carbon compounds containing a hetero ring having chalcogen (i.e., O,S,Se or Te) or nitrogen as the only ring hetero atoms DOAI

514359000 - Five-membered hetero ring containing at least one nitrogen ring atom (e.g., 1,2,3-triazoles, etc.)

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
514380000 Chalcogen or nitrogen bonded directly to ring carbon of the oxazole ring 28
514379000 Polycyclo ring system having the oxazole ring as one of the cyclos 14
Entries
DocumentTitleDate
20100035948Furanone compounds and lactam analogues thereof - The present invention provides a compound of formula I and a compound of formula II, methods of use and formulations thereof.02-11-2010
20100160398Farnesoid X Receptor Agonists - The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.06-24-2010
20090042957Substituted Oxyarenes - The invention relates to compounds of the formula (I)02-12-2009
20130046001PHARMACEUTICAL COMPOSITION FOR INHIBITING APOPTOSIS OF NEURON OR NEURODEGENERATION - Provided is a pharmaceutical composition for inhibiting apoptosis of neurons or neurodegeneration. The pharmaceutical composition effectively prevents or treats diseases related to apoptosis of neurons or neurodegeneration.02-21-2013
20090306158Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators 286 - Compounds in accord with Formula I:12-10-2009
20130165490INSECTICIDAL COMPOUNDS - A compound of formula (I):06-27-2013
20100273844PHARMACEUTICAL COMPOSITIONS FOR TREATING OR PREVENTING MIGAINES - The present invention provides a method for treating or preventing one or more types of migraines by administering a monoamine oxidase inhibitor, preferably isocarboxazid, in a rapid-release formulation. The present invention also provides a pharmaceutical composition suitable for treating or preventing migraines and having at least one monoamine oxidase inhibitor.10-28-2010
20090099244ORGANIC COMPOUNDS - The invention relates to compound of the formula I04-16-2009
20090143451COMPOUNDS THAT INCREASE TELOMERASE REVERSE TRANSCRIPTASE (TERT) EXPRESSION AND METHODS FOR USING THE SAME - Compounds, and methods of using the same, are provided which increase the expression of telomerase reverse transcriptase (TERT) in a cell. These compounds and methods find use in a variety of applications in which increased expression of telomerase is desired, including immortalization of cell lines and treating conditions in a subject characterized by cellular senescence.06-04-2009
20090062356SUBSTITUTED BENZIMIDAZOLE DERIVATIVES - The invention is concerned with novel substituted benzimidazole derivatives of formula (I)03-05-2009
20090042958Composition and method for treating immune-mediated skin disorders - Liquid or semi-liquid pharmaceutical compositions for topically treating immune-mediated skin disorders such as psoriasis, eczema, acne, dermatitis, and skin cancer and methods of treating patients having such immune-mediated skin disorders using the compositions.02-12-2009
20090170916Pyrrole and Pyrazole DAAO Inhibitors - Methods for increasing D-Serine concentration and reducing concentration of the toxic products of D-Serine oxidation, for enhancing learning, memory and/or cognition, or for treating schizophrenia, Alzheimer's disease, ataxia or neuropathic pain, or preventing loss in neuronal function characteristic of neurodegenerative diseases involve administering to a subject in need of treatment a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof:07-02-2009
20080262057Diarylisoxazolines - The invention disclosed in this document is related to field of pesticides and their use in controlling pests.10-23-2008
20130217737Use of Malononitrilamides in Neuropathic Pain - Provided herein are compounds and pharmaceutical compositions for use in the treatment of neuropathic pain and the neuropathic pain syndromes.08-22-2013
20130217736Naphthalene Isoxazoline Invertebrate Pest Control Agents - Disclosed are compounds of Formula 1,08-22-2013
20090186927TRANS-9,10-DEHYDROEPOTHILONE C AND D, ANALOGS THEREOF AND METHODS OF MAKING THE SAME - The present invention provides new trans-9,10-dehydroepothilone C and trans-9,10-dehydroepothilone D based derivative compounds, compositions and methods of inhibiting cellular hyperproliferation and/or stabilizing microtubules in vitro and of treatment of hyperproliferative diseases in vivo. Also disclosed are methods of making the compounds.07-23-2009
20090042959COMPOUNDS HAVING IMMUNOMODULATOR ACTIVITY - Compounds of formula I02-12-2009
20090137647Modified Macrophage Migration Inhibitory Factor Inhibitors - Provided are various compounds of Formula I (I). Also provided are various compounds of Formula II (II). Also provided are pharmaceutical compositions comprising the above compounds. Additionally, methods of inhibiting macrophage migration inhibitory factor (MIF) activity in a mammal are provided, as are methods of treating or preventing inflammation in a mammal. Further provided are methods of treating a mammal having sepsis, septicemia, and/or endotoxic shock. Also providcd are methods of treating a mammal having an autoimmune disease, and methods of treating a mammal having a tumor.05-28-2009
20090048315Method of alleviating chronic pain via peripheral glutaminase regulation - A composition having sustained pain-relieving properties such that the composition may be administered to a subject to alleviate chronic pain. The composition includes an effective amount of at least one glutaminase inhibitor. A method for alleviating chronic pain in a subject for an extended period of time is also disclosed, in which the compound is administered to a subject suffering from chronic pain at a site of inflammation such that the administration of the compound results in a reduction in at least one of thermal and mechanical pain responses at the site of inflammation for a period of at least two days without any resulting acute pain behavior. The composition may further include an effective amount of at least one compound having analgesic effects such that the composition also alleviates acute pain.02-19-2009
20090298898PESTICIDALLY ACTIVE KETONE AND OXIME DERIVATIVES - Compounds of formula12-03-2009
20100261772Cycloalkylidene Compounds As Selective Estrogen Receptor Modulators - The present invention relates to compounds of formula (I) with a variety of therapeutic uses, more particularly the substituted cyclic alkylidene compounds are useful for selective estrogen receptor modulation.10-14-2010
20130190369MODIFIED MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS - Provided are various compounds of Formula I (I). Also provided are various compounds of Formula II (II). Also provided are pharmaceutical compositions comprising the above compounds. Additionally, methods of inhibiting macrophage migration inhibitory factor (MIF) activity in a mammal are provided, as are methods of treating or preventing inflammation in a mammal. Further provided are methods of treating a mammal having sepsis, septicemia, and/or endotoxic shock. Also provided are methods of treating a mammal having an autoimmune disease, and methods of treating a mammal having a tumor.07-25-2013
20130123314METHOD FOR IMPROVING CARTILAGE REPAIR AND/OR PREVENTING CARTILAGE DEGENERATION IN A JOINT - The invention is in the field of methods for medical treatment. It provides an improved method for repairing damaged cartilage and/or preventing cartilage degeneration in tissue, in particular in a joint by administering a pharmaceutically active agent directly into the fat pad of a joint. The pharmaceutically active agent is preferably selected from the group consisting of agents that stimulate chondrogenic differentiation and/or cartilage matrix synthesis; agents that inhibit osteogenesis and/or hypertrophy, anti-inflammatory agents, agents that inhibit apoptosis of chondrocytes, agents that inhibit senescence of chondrocytes and agents that enhance lubrication of a joint.05-16-2013
20100267784NOVEL 4,5-DIHYDROISOXAZOLES WITH ESTROGENIC ACTIVITY - This invention relates to novel 4,5-dihydroisoxazoles of formula (I), to their use as estrogen receptor modulators, and to methods of their preparation.10-21-2010
20090163562ORAL COMPOSITION COMPRISING 3-[5-[4-(CYCLOPENTYLOXY) -2-HYDROXYBENZOYL]-2-[(3-HYDROXY-1,2-BENZISOXAZOL-6- YL)METHOXY]PHENYL]PROPIONIC ACID OR SALT THEREOF - An oral composition contains 3-{5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-hydroxy-1,2-benzisoxazol-6-yl)methoxy]phenyl}propionic acid or a salt thereof and polyvinylpyrrolidone is advantageous as an oral medication composition (1) which can be produced without requiring new manufacturing equipment; (2) which can be produced with simple steps; (3) which maintains stable solubility even with changes in the pH of the gastrointestinal tract and of which gastrointestinal tract absorption is improved.06-25-2009
20090318516SOLID FORMS OF (1R,2S,3R)-1-(2-(ISOXAZOL-3-YL)-1H-IMIDAZOL-4-YL)BUTANE-1,2,3,4-TETRAOL AND METHODS OF THEIR USE - Solid forms of (1R,2S,3R)-1-(2-(isoxazol-3-yl)-1H-imidazol-4-yl)butane-1,2,3,4-tetraol and hydrates thereof are disclosed, as well as compositions comprising them and methods of their use.12-24-2009
20130137735CRYSTALLINE FORM OF 4- [5 - [3 -CHLORO-5 - (TRIFLUOROMETHYL) PHENYL] -4, 5 - DIHYDRO - 5 - (TRIFLUOROMETHYL) -3 - ISOXAZOLYL] -N- [2-0X0-2- [ ( 2, 2, 2 - TRIFLUOROETHYL) AMINO] ETHYL] -1- NAPH-THALENECARBOXAMIDE - Disclosed is a solid form of 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-N-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-1-naphthalenecarboxamide (Compound 1). Also disclosed are compositions containing a solid form of Compound 1 and methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a solid form of Compound 1 or a composition containing a solid form of Compound 1.05-30-2013
20090076103STEM CELL DIFFERENTIATING AGENTS AND USES THEREFOR - The present invention relates to screens for compounds that can induce stem cell differentiation. In addition, isoxazoles and sulfonyl hydrazones are identified as general classes of compounds that can induce differentiation of stem cells into cells of neuronal and cardiac fate, respectively.03-19-2009
20110130432Heterocyclic Carboxamides For Use As Thrombin Inhibitors - This invention relates to novel pharmaceutically useful compounds of formula (I), in particular compounds that are competitive inhibitors of trypsin-like serine proteases, especially thrombin, their use as medicaments, pharmaceutical compositions containing them and synthetic routes to their production. Formula (I)06-02-2011
20100240722FLUORINE-CONTAINING ORGANOSULFUR COMPOUND AND PESTICIDAL COMPOSITION COMPRISING THE SAME - There is provided a fluorine-containing organosulfur compound having an excellent controlling effect m represents 0 or 1; n represents 0, 1 or 2; A represents an optionally substituted 5-membered aromatic heterocyclic group; R09-23-2010
20100144808SUBSTITUTED ISOXAZOLINE OR ENONE OXIME COMPOUND, AND PEST CONTROL AGENT - Disclosed is a novel pest control agent, in particular a pesticide or a miticide. Specifically disclosed are a substituted isoxazoline compound or a substituted enone oxime compound represented by the general formula (1) below or the general formula (2) below, and a pest control agent containing any of them. (In the formulae, the symbols are as defined in the description.)06-10-2010
20080214636Glycyrrhetinic Acid-30-Amide Derivatives and Their Use - The present invention relates to the field of a medicine for treating diseases associated with inflammation, immunity or infection, and in particular, to glycyrrhetinic acid-30-amide derivatives of general formula I and their preparation, and a pharmaceutical composition containing the same. Said derivatives and composition exhibit anti-inflammatory, analgesic, anti-allergic, cough-preventing, liver-protecting and anti-viral properties,09-04-2008
20110166193INSECTICIDAL COMPOUNDS - A compound of Formula (I): where A07-07-2011
20110201661Spiro Derivatives of Parthenin as Novel Anticancer Agents - The present invention relates to novel spiro derivatives of parthenin prepared by the dipolar cycloaddition of various dipoles viz, benzonitrile oxides, nitrones, azides, nitrile ylide diazoalkane, nitrile imide, ozone, azomethine imides, azomethine ylides etc. with exocyclic double bond of C ring (α-methylene-γ-butyrolactone). Representative compounds have been screened for their anticancer activity against different cancer cell lines. ICs0 value of these analogues varies between 4.3 μM to 93 μM. A mechanistic correlation of their anticancer activity has been described. The results of the cytotoxicity test of the compounds studies indicated that the α,β-unsaturated ketonic moiety in parthenin plays an important role in the maintenance of the high level of cytotoxicity.08-18-2011
20100022608Non-steroidal anti-inflammatory drugs for cough - The use of a non-steroidal anti-inflammatory drug for the treatment of nonproductive cough caused by viruses or bacteria and a combination of at least one non-steroidal anti-inflammatory drug with at least one antitussive in a formulation to treat coughs.01-28-2010
20100016391Isoxazoline Compounds Having MIF Antagonist Activity - Methods of use and pharmaceutical compositions for a genus of low molecular weight compounds comprising optionally substituted isoxazoline ring systems that act as inhibitors of MIF (macrophage migration inhibitory factor) are disclosed. Specifically, the compounds are useful for treating a variety of diseases involving inflammatory activity or pro-inflammatory cytokine responses, such as autoimmune diseases (including rheumatoid arthritis, insulin-dependent diabetes, multiple sclerosis, graft versus host disease, lupus syndromes), asthma, arthritis, ARDS, psoriasis, interleukin-2 toxicity, proliferative vascular disease, and various forms of sepsis and septic shock, and other conditions characterized by underlying MIF responses including, for instance, tumor growth and neovascularization (angiogenesis).01-21-2010
20090197928Novel Receptor Antagonists and Their Methods of Use - The present invention relates to novel isoxazole derivatives of formula (I) which bind to the P2X7 receptor and are capable of interfering with the effects of ATP at the P2X7 receptor:08-06-2009
20120046325Isoxazoline Compounds Having MIF Antagonist Activity - Methods of use and pharmaceutical compositions for a genus of low molecular weight compounds comprising optionally substituted isoxazoline ring systems that act as inhibitors of MIF (macrophage migration inhibitory factor) are disclosed. Specifically, the compounds are useful for treating a variety of diseases involving inflammatory activity or pro-inflammatory cytokine responses, such as autoimmune diseases (including rheumatoid arthritis, insulin-dependent diabetes, multiple sclerosis, graft versus host disease, lupus syndromes), asthma, arthritis, ARDS, psoriasis, interleukin-2 toxicity, proliferative vascular disease, and various forms of sepsis and septic shock, and other conditions characterized by underlying MIF responses including, for instance, tumor growth and neovascularization (angiogenesis).02-23-2012
201100657645- PHENYL-ISOXAZOLE-3-CARBOXAMIDE DERIVATIVES AS TRPV1 MODULATORS - The present invention relates to isoxazole-3-carboxamide derivative having the general Formula (I), or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same, as well as to the use of said isoxazole-3-carboxamide derivatives for the treatment of TRPV1 mediated disorders, such as acute and chronic pain disorders, acute and chronic neuropathic pain, acute and chronic inflammatory pain, respiratory diseases, and lower urinary tract disorders.03-17-2011
20100048652INSECTICIDAL COMPOUNDS - A compound of formula (I): wherein A02-25-2010
20120322840Transdermally Absorbable Preparation Containing Basic Anti-Inflammatory Analgesic - A transdermally absorbable preparation in which a basic anti-inflammatory analgesic is formulated is provided to be an external adhesive patch, which has excellent drug releasing without damaging the physical properties of a plaster. The preparation can achieve high releasing of the basic anti-inflammatory analgesic without losing the releasing of the local anesthetic. Specifically provided is a transdermally absorbable adhesive patch, which contains both the basic anti-inflammatory analgesic and the local anesthetic as the absorption promoter for the basic anti-inflammatory analgesic. The basic anti-inflammatory analgesic has the acid dissociation constant (pKa) of 7 or more. The content of the basic anti-inflammatory analgesic is from 0.1% to 10% by weight to the total weight of the drug-containing plaster, and the content of the absorption promoter is from 0.01% to 20% by weight to the total weight of the drug-containing plaster in the transdermally absorbable adhesive patch.12-20-2012
20110237633SMALL MOLECULE MODULATORS OF HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY - The present invention provides compounds and pharmaceutically acceptable compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases in which hepatocyte growth factor/scatter factor (HGF/SF) or the activities thereof, or agonists or antagonists thereof, have a therapeutically useful role.09-29-2011
20110160259Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners - One aspect of the present invention relates to heterocyclic compounds that bind to bcl proteins and inhibit Bcl function. Another aspect of the present invention relates to compositions comprising a heterocyclic compound of the invention. The present invention provides methods for treating and modulating disorders associated with hyperproliferation, such as cancer.06-30-2011
20130178506ISOXAZOLE TREATMENTS FOR DIABETES - The present invention relates to compounds and methods for inducing synthesis and secretion of insulin from pancreatic beta cells. The methods may take place in vitro, ex vivo such as in isolates from adult mammalian tissue, or in vivo. Compounds and methods described herein may find use in the treatment of diabetes.07-11-2013
20130143935STEM CELL DIFFERENTIATING AGENTS AND USES THEREFOR - The present invention relates to screens for compounds that can induce stem cell differentiation. In addition, isoxazoles and sulfonyl hydrazones are identified as general classes of compounds that can induce differentiation of stem cells into cells of neuronal and cardiac fate, respectively.06-06-2013
20110251247SUBSTITUTED ISOXAZOLINE DERIVATIVES - This invention recites substituted isoxazoline derivatives of Formula (1)10-13-2011
20100305176(S,R.)-3-PHENYL-4,5 DIHYDRO-5-ISOXAZOLE ACETIC ACID-NITRIC OXIDE AND USE THEREOF AS ANTI-CANCER AND ANTIVIRAL AGENT - The present invention relates to an isoxazole derivative, the compound of formula (I)12-02-2010
20120029040ANIMAL ECTOPARASITE-CONTROLLING AGENT - The present invention provides an animal ectoparasite-controlling agent containing as an active ingredient a hydrazide compound represented by the formula (1)02-02-2012
20120029039ANIMAL ECTOPARASITE-CONTROLLING AGENT - The present invention provides an animal ectoparasite-controlling agent containing as an active ingredient a hydrazide compound represented by the formula (1)02-02-2012
20120029038ANIMAL ECTOPARASITE-CONTROLLING AGENT - The present invention provides an animal ectoparasite-controlling agent containing as an active ingredient a hydrazide compound represented by the formula (1)02-02-2012
20120029037ANIMAL ECTOPARASITE-CONTROLLING AGENT - The present invention provides an animal ectoparasite-controlling agent containing as an active ingredient a hydrazide compound represented by the formula (1)02-02-2012

Patent applications in class 1,2-oxazoles (including hydrogenated)

Patent applications in all subclasses 1,2-oxazoles (including hydrogenated)